Heparin-binding domains in vascular biology

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 24, Issue 9, 2004, Pages 1549-1557

  Muñoz, Eva M ^a   Linhardt, Robert J ^a,b  

^a Research Rensselaer Polytechnic Institute   (United States)

^b RENSSELAER POLYTECHNIC INSTITUTE   (United States)

Author keywords

Antithrombin; Basic amino acids; Consensus sequence; Glycosaminoglycan; Heparin binding domains

Indexed keywords

AMINO ACID; ANTITHROMBIN; GLYCOSAMINOGLYCAN; HEPARAN SULFATE; HEPARIN; HEPARIN BINDING PROTEIN;

ANTICOAGULATION; BINDING SITE; BLOOD VESSEL; CRYSTAL STRUCTURE; PRIORITY JOURNAL; PROTEIN BINDING; SHORT SURVEY; SITE DIRECTED MUTAGENESIS; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; ANIMALS; ANTITHROMBINS; BINDING SITES; BLOOD PROTEINS; CARBOHYDRATE SEQUENCE; CARDIOVASCULAR AGENTS; CARDIOVASCULAR SYSTEM; CONSENSUS SEQUENCE; DRUG DESIGN; HEPARIN; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, TERTIARY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 4444342956     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000137189.22999.3f     Document Type: Short Survey

References (107)

1. Brinkhous KM, Smith HP, Warner ED, Seegers WH. The inhibition of blood clotting: an unidentified substance which acts in conjunction with heparin to prevent the conversion of prothrombin into thrombin. Am J Physiol. 1939;125:683-687.
2. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh. 1965;13:516-530.
3. Rosenberg RD, Damus PS. The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem. 1973;248: 6490-6505.
4. Tyrrell DJ, Kilfeather S, Page CP. Therapeutic uses of heparin beyond its traditional role as an anticoagulant. Trends Pharmacol Sci. 1995;16: 198-204.
5. Capila I, Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed Engl. 2002;41:390-412.
6. Linhardt RJ. 2003 Claude S. Hudson Award address in carbohydrate chemistry. Heparin: structure and activity. J Med Chem. 2003;46: 2551-2564.
7. Comper WD. Heparin and Related Polysaccharides. Vol 7. New York, NY: Gordon Breach; 1981.
8. Bae J, Desai UR, Pervin A, Caldwell EE, Weiler JM, Linhardt RJ. Interaction of heparin with synthetic antithrombin III peptide analogues. Biochem J. 1994;301:121-129.
9. Hileman RE, Jennings RN, Linhardt RJ. Thermodynamic analysis of the heparin interaction with a basic cyclic peptide using isothermal titration calorimetry. Biochemistry. 1998;37:15231-15237.
10. Path MA, Wu X, Hileman RE, Linhardt RJ, Kashem MA, Nelson RM, Wright CD, Abraham WM. Interaction of secretory leukocyte protease inhibitor with heparin inhibits proteases involved in asthma. J Biol Chem. 1998;273:13563-13569.
11. Jairajpuri MA, Lu A, Desai U, Olson ST, Bjork I, Bock SC. Antithrombin III phenylalanines 122 and 121 contribute to its high affinity for heparin and its conformational activation. J Biol Chem. 2003;278: 15941-15950.
12. Petitou M, Casu B, Lindahl U. 1976-1983, a critical period in the history of heparin: the discovery of the antithrombin binding site. Biochimie. 2003;85:83-89.
13. Faham S, Hileman RE, Fromm JR, Linhardt RJ, Rees DC. Heparin structure and interactions with basic fibroblast growth factor. Science. 1996;271:1116-1120.
14. Faham S, Linhardt RJ, Rees DC. Diversity does make a difference: fibroblast growth factor-heparin interactions. Curr Opin Struct Biol. 1998;8:578-586.
15. Schlessinger J, Plotnikov AN, Ibrahimi OA, Eliseenkova AV, Yeh BK, Yayon A, Linhardt RJ, Mohammadi M. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell. 2000;6:743-750.
16. Pellegrini L, Burke DF, von Delft F, Mulloy B, Blundell TL. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature. 2000;407:1029-1034.
17. Yeh BK, Eliseenkova AV, Plotnikov AN, Green D, Pinnell J, Polat T, Gritli-Linde A, Linhardt RJ, Mohammadi M. Structural basis for activation of fibroblast growth factor signaling by sucrose octasulfate. Mol Cell Biol. 2002;22:7184-7192.
18. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, Marks RM. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med. 1997;3:866-871.
19. Shukla D, Liu J, Blaiklock P, Shworak NW, Bai X, Esko JD, Cohen GH, Eisenberg RJ, Rosenberg RD, Spear PG. A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell. 1999;99:13-22.
20. Marks RM, Lu H, Sundaresan R, Toida T, Suzuki A, Imanari T, Hernaiz MJ, Linhardt RJ. Probing the interaction of dengue virus envelope protein with heparin: assessment of glycosaminoglycan-derived inhibitors. J Med Chem. 2001;44:2178-2187.
21. Liu J, Shriver Z, Pope RM, Thorp SC, Dunean MB, Copeland RJ, Raska CS, Yoshida K, Eisenberg RJ, Cohen G, Linhardt RJ, Sasisekharan R. Characterization of a heparan sulfate octasaccharide that binds to herpes simplex virus type 1 glycoprotein D. J Biol Chem. 2002;277: 33456-33467.
22. Hileman RE, Fromm JR, Weiler JM, Linhardt RJ. Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. BioEssays. 1998;20:156-167.
23. Cardin AD, Weintraub HJ. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis. 1989;9:21-32.
24. Margalit H, Fischer N, Ben-Sasson SA. Comparative analysis of structurally defined heparin binding sequences reveals a distinct spatial distribution of basic residues. J Biol Chem. 1993;268:19228-19231.
25. Fromm JR, Hileman RE, Caldwell EE, Weiler JM, Linhardt RJ. Pattern and spacing of basic amino acids in heparin binding sites. Arch Biochem Biophys. 1997;343:92-100.
26. Fromm JR, Hileman RE, Caldwell EEO, Weiler JM, Linhardt RJ. Differences in the interaction of heparin with arginine and lysine and the importance of these basic amino acids in the binding of heparin to acidic fibroblast growth factor. Arch Biochem Biophys. 1995;323:279-287.
27. Pearson RG. Hard and soft acids and bases. J Am Chem Soc. 1963;85: 3533-3539.
28. Caldwell EE, Nadkarni VD, Fromm JR, Linhardt RJ, Weiler JM. Importance of specific amino acids in protein binding sites for heparin and heparan sulfate. Int J Biochem Cell Biol. 1996;28:203-216.
29. Verrecchio A, Germann MW, Schick BP, Kung B, Twardowski T, San Antonio JD. Design of peptides with high affinities for heparin and endothelial cell proteoglycans. J Biol Chem. 2000;275:7701-7707.
30. Mulloy B, Linhardt RJ. Order out of complexity-protein structures that interact with heparin. Curr Opin Struct Biol. 2001;11:623-628.
31. Moy FJ, Seddon AP, Bohlen P, Powers R. High-resolution solution structure of basic fibroblast growth factor determined by multidimensional heteronuclear magnetic resonance spectroscopy. Biochemistry. 1996;35:13552-13561.
32. Peters-Libeu C, Lund-Katz S, Phillips M, Wehrli S, Hemáiz MJ, Capila I, Linhardt RJ, Raffai R, Newhouse YM, Zhou FM, Weisgraber KH. New insights into the heparan sulfate proteoglycan-binding activity of apolipoprotein E4. J Biol Chem. 2001;276:39138-39142.
33. Mikhailov D, Young HC, Linhardt RJ, Mayo KH. Heparin dodecasaccharide- binding to platelet factor-4 and growth-related protein-introduction of a partially folded state and implications for heparin-induced thrombocytopenia. J Biol Chem. 1999;274:25317-25329.
34. Peterson FC, Elgin ES, Nelson TJ, Zhang F, Hoeger TJ, Linhardt RJ, Volkman BF. Identification and characterization of a glycosaminoglycan recognition element of the C chemokine lymphotactin. J Biol Chem. 2004;279:12598-12604.
35. Evans DL, Marshall CJ, Christey PB, Carrell RW. Heparin binding site, conformational change, and activation of antithrombin. Biochemistry. 1992:31:12629-12642.
36. Thompson LD, Pantoliano MW, Springer BA. Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain. Biochemistry. 1994;33: 3831-3840.
37. Mellet P, Ermolieff J, Bieth JG. Mapping the heparin-binding site of mucus proteinase inhibitor. Biochemistry. 1995;34:2645-2652.
38. Sasisekharan R, Venkataraman G, Godavarti R, Ernst S, Cooney CL, Langer R. Heparinase I from Flavobacterium heparinum. Mapping and characterization of the heparin binding domain. J Biol Chem. 1996;271: 3124-3131.
39. Raut S, Gaffney PJ. Interaction of heparin with fibrinogen using surface plasmon resonance technology: investigation of heparin binding site on fibrinogen. Thromb Res. 1996;81:503-509.
40. Meagher JL, Huntington JA, Fan B, Gettins PGW. Role of arginine 132 and lysine 133 in heparin binding to and activation of antithrombin. J Biol Chem. 1996;271:29353-29358.
41. Ersdal-Badju E, Lu A, Zuo Y, Picard V, Bock SC. Identification of the antithrombin III heparin binding site. J Biol Chem. 1997;272: 19393-19400.
42. Delacoux F, Fichard A, Geourjon C, Garrone R, Ruggiero F. Molecular features of the collagen V heparin binding site. J Biol Chem. 1998;273: 15069-15076.
43. Zhao M, Abdel-Razek T, Sun M-F, Gailani D. Characterization of a heparin binding site on the heavy chain of factor XI. J Biol Chem. 1998;273:31153-31159.
44. Bitomsky W, Wade RC. Docking of glycosaminoglycans to heparin-binding proteins: validation for aFGF, bFGF, and antithrombin and application to IL-8. J Am Chem Soc. 1999;121:3004-3013.
45. Montserret R, Aubert-Foucher E, McLeish MJ, Hill JM, Ficheux D, Jaquinod M, van der Rest M, Deleage G, Penin F. Structural analysis of the heparin-binding site of the NCl domain of collagen XIV by CD and NMR. Biochemistry. 1999;38:6479-6488.
46. Patrie KM, Botelho MJ, Franklin K, Chiu I-M. Site-directed mutagenesis and molecular modeling identify a crucial amino acid in specifying the heparin affinity of FGF-1. Biochemistry. 1999;38: 9264-9272.
47. Zhou H, Casas-Finet JR, Coats RH, Kaufman JD, Stahl SJ, Wingfield PT, Rubin JS, Bottaro DP, Byrd RA. Identification and dynamics of a heparin-binding site in hepatocyte growth factor. Biochemistry. 1999; 38:14793-14802.
48. Rezaie AR, Identification of basic residues in the heparin-binding exosite of factor Xa critical for heparin and factor Va binding, J Biol Chem. 2000;275:3320-3327.
49. Badellino KO, Walsh PN, Localization of a Heparin Binding Site in the Catalytic Domain of Factor XIa, Biochemistry. 2001;40;7569-7580.
50. Friedrich U, Blom AM, Dahlback B, Villoutreix BO. Structural and energetic characteristics of the heparin-binding site in antithrombotic protein C. J Biol Chem. 2001;276:24122-24128.
51. Bellosta P, Iwahori A, Plotnikov AN, Eliseenkova AV, Basilico C, Mohammadi M. Identification of receptor and heparin binding sites in fibroblast growth factor 4 by structure-based mutagenesis. Mol Cell Biol. 2001;21:5946-5957,
52. Campanella GSV, Lee EMJ, Sun J, Luster AD. CXCR3 and heparin binding sites of the chemokine IP-10 (CXCL10). J Biol Chem. 2003; 278:17066-17074.
53. Olson ST, Bjork I, Bock SC. Identification of critical molecular interactions mediating heparin activation of antithrombin implications for the design of improved heparin anticoagulants. Trends Cardiovasc Med. 2002;12:198-205.
54. Olson ST, Srinivasan KR, Bjoerk I, Shore JD. Binding of high-affinity heparin to antithrombin III. Stopped flow kinetic studies of the binding interaction. J Biol Chem. 1981;256:11073-11079.
55. Olson ST, Bjork I, Sheffer R, Craig PA, Shore JD, Choay J. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement. J Biol Chem. 1992;267:12528-12538.
56. Bjoerk I, Nordling K. Evidence by chemical modification for the involvement of one or more tryptophanyl residues of bovine antithrombin in the binding of high-affinity heparin. Eur J Biochem. 1979; 102:497-502.
57. Blackburn MN, Sibley CC. The heparin binding site of antithrombin III. Evidence for a critical tryptophan residue. J Biol Chem. 1980;255: 824-826.
58. Blackburn MN, Smith RL, Carson J, Sibley CC. The heparin-binding site of antithrombin III. Identification of a critical tryptophan in the amino acid sequence. J Biol Chem. 1984;259:939-941.
59. Liu CS, Chang JY. The heparin binding site of human antithrombin III. Selective chemical modification at Lys114, Lys125, and Lys287 impairs its heparin cofactor activity. J Biol Chem. 1987;262:17356-17361.
60. Peterson CB, Noyes CM, Pecon JM, Church FC, Blackburn MN. Identification of a lysyl residue in antithrombin which is essential for heparin binding. J Biol Chem. 1987;262:8061-8065.
61. Chang JY. Binding of heparin to human antithrombin III activates selective chemical modification at lysine 236. Lys-107, Lys-125, and Lys-136 are situated within the heparin-binding site of antithrombin III. J Biol Chem. 1989;264:3111-3115.
62. Gandrille S, Aiach M, Lane DA, Vidaud D, Molho-Sabatier P, Caso R, de Moerloose P, Fiessinger JN, Clauser E. Important role of arginine 129 in heparin-binding site of antithrombin III. Identification of a novel mutation arginine 129 to glutamine. J Biol Chem. 1990;265: 18997-19001.
63. Shah N, Scully MF, Ellis V, Kakkar VV. Influence of chemical modification of tryptophan residues on the properties of human antithrombin III. Thromb Res. 1990;57:343-352.
64. Sun XJ, Chang JY. Evidence that arginine-129 and arginine-145 are located within the heparin binding site of human antithrombin III. Biochemistry. 1990;29:8957-8962.
65. Jin L, Abrahams JP, Skinner R, Petitou M, Pike RN, Carrell RW. The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci U S A. 1997;94:14683-14688.
66. Arocas V, Turk B, Bock SC, Olson ST, Bjork I. The region of antithrombin interacting with full-length heparin chains outside the high-affinity pentasaccharide sequence extends to Lys136 but not to Lys139. Biochemistry. 2000;39:8512-8518.
67. Skinner R, Abrahams JP, Whisstock JC, Lesk AM, Carrell RW, Wardell MR. The 2.6 Å structure of antithrombin indicates a conformational change at the heparin binding site. J Mol Biol. 1997;266:601-609.
68. Huntington JA, Olson ST, Fan B, Gettins PG. Mechanism of heparin activation of antithrombin. Evidence for reactive center loop preinsertion with expulsion upon heparin binding. Biochemistry. 1996;35: 8495-8503,
69. Huntington JA, McCoy A, Belzar KJ, Pei XY, Gettins PG, Carrell RW. The conformational activation of antithrombin, A 2.85 Å structure of a fluorescein derivative reveals an electrostatic link between the hinge and heparin binding regions. J Biol Chem. 2000;275:15377-15383.
70. Chuang YJ, Swanson R, Raja SM, Olson ST. Heparin enhances the specificity of antithrombin for thrombin and factor Xa independent of the reactive center loop sequence. Evidence for an exosite determinant of factor Xa specificity in heparin-activated antithrombin. J Biol Chem. 2001;276:14961-14971.
71. Desai U, Swanson R, Bock SC, Bjork I, Olson ST. Role of arginine 129 in heparin binding and activation of antithrombin. J Biol Chem. 2000; 275:18976-18984.
72. Arocas V, Bock SC, Raja S, Olson ST, Bjork I, Lysine 114 of antithrombin is of crucial importance for the affinity and kinetics of heparin pentasaccharide binding. J Biol Chem. 2001;276:43809-43817.
73. Schedin-Weiss S, Arocas V, Bock SC, Olson ST, Bjoerk I. Specificity of the basic side chains of Lys114, Lys125, and Arg129 of antithrombin in heparin binding. Biochemistry. 2002;41:12369-12376.
74. Arocas V, Bock SC, Olson ST, Bjork I. The role of Arg46 and Arg47 of antithrombin in heparin binding. Biochemistry. 1999;38:10196-10204.
75. Schedin-Weiss S, Desai UR, Bock SC, Olson ST, Bjoerk I. Roles of N-terminal region residues Lys11, Arg13, and Arg24 of antithrombin in heparin recognition and in promotion and stabilization of the heparin-induced conformational change. Biochemistry. 2004;43:675-683.
76. Schedin-Weiss S, Desai UR, Bock SC, Gettins PGW, Olson ST, Bjoerk I. Importance of lysine 125 for heparin binding and activation of antithrombin. Biochemistry. 2002;41:4779-4788.
77. Olson ST, Bjork I. Predominant contribution of surface approximation to the mechanism of heparin acceleration of the antithrombin-thrombin reaction. Elucidation from salt concentration effects. J Biol Chem. 1991; 266:6353-6364.
78. Turk B, Brieditis I, Bock SC, Olson ST, Bjork I. The oligosaccharide side chain on Asn-135 of alpha-antithrombin, absent in beta-antithrombin, decreases the heparin affinity of the inhibitor by affecting the heparin-induced conformational change. Biochemistry. 1997;36: 6682-6691.
79. Fry EE, Lea SM, Jackson T, Newman JWI, Ellard FM, Blakemore WE, Abu-Ghazaleh R, Samuel A, King AMQ, Stuart DI. The structure and function of a foot-and-mouth disease virus-oligosaccharide receptor complex. EMBO J. 1999;18:543-554.
80. Capila I, Hernáiz MJ, Mo YD, Mealy TR, Campos B, Linhardt RJ, Seaton BA. Annexin V-heparin oligosaccharide complex suggests heparan sulfate-mediated assembly on cell surfaces Structure (Camb). 2001;9:57-64.
81. Lietha D, Chirgadze DY, Mulloy B, Blundell TL, Gherardi E. Crystal structures of NK1-heparin complexes reveal the basis for NK1 activity and enable engineering of potent agonists of the MET receptor. EMBO J. 2001;20:5543-5555.
82. Moon AF, Edavettal SC, Krahn JM, Munoz EM, Negishi M, Linhardt RJ, Liu J, Pedersen LC. Structural analysis of the sulfotransferase (3-OST-3) involved in the biosynthesis of an entry receptor for herpes simplex virus 1. J Biol Chem. 2004;279:25789-25797.
83. Kuschert GSV, Hoogewerf AJ, Proudfoot AEI, Chung C-W, Cooke RM, Hubbard RE, Wells TNC, Sanderson PN. Identification of a glycosaminoglycan binding surface on human interleukin-8. Biochemistry. 1998; 37:11193-11201.
84. Ogura K, Nagata K, Hatanaka H, Habuchi H, Kimata K, Tate S-I, Ravera MW, Jaye M, Schlessinger J, Inagaki F. Solution structure of human acidic fibroblast growth factor and interaction with heparin-derived hexasaccharide. J Biomol NMR. 1999;13:11-24.
85. Kilpeläinen I. Kaksonen M, Kinnunen T, Avikainen H, Linhardt RJ, Fath M, Raulo E, Rauvala H. Heparin-binding growth-associated molecule contains two heparin-binding β-sheet domains that are homologous to the thrombospondin type I repeat. J Biol Chem. 2000; 275:13564-13570.
86. Ferro DR, Choay J. Evidence for conformational equilibrium of the sulfated L-iduronate residue in heparin and in synthetic heparin mono- and oligosaccharides: NMR and force-field studies. J Am Chem Soc. 1986;108:6773-6778.
87. Mulloy B, Forster MJ. Conformation and dynamics of heparin and heparan sulfate. Glycobiology. 2000;10:1147-1156.
88. Mikhailov D, Mayo KH, Vlahov IR, Toida T, Pervin A, Linhardt RJ. NMR solution conformation of heparin-derived tetrasaccharide. Biochem J. 1996;318:93-102.
89. Esko JD, Selleck SB. Order out of chaos: assembly of ligand binding sites in heparan sulfate. Annu Rev Biochem. 2002;71:435-471.
90. Bernfield M, Kokenyesi R, Kato M, Hinkes MT, Spring J, Gallo RL, Lose EJ. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu Rev Cell Biol. 1992;8:365-393.
91. Marcum JA, Rosenberg RD. Heparinlike molecules with anticoagulant activity are synthesized by cultured endothelial cells. Biochem Biophys Res Commun. 1985;126:365-372.
92. Garg HG, Joseph PAM, Thompson BT, Hales CA, Toida T, Imanari T, Capila I, Linhardt RJ. Effect of fully sulfated glycosaminoglycans on pulmonary artery smooth muscle cell proliferation. Arch Biochem Biophys. 1999;371:228-233.
93. HajMohammadi S, Enjyoji K, Princivalle M, Christi P, Lech M, Beeler D, Rayburn H, Schwartz JJ, Barzegar S, de Agostini AI, Post MJ, Rosenberg RD, Shworak NW. Normal levels of anticoagulant heparan sulfate are not essential for normal hemostasis. J Clin Invest. 2003;111: 989-999.
94. Weitz JI. Heparan sulfate: antithrombotic or not? J Clin Invest. 2003; 111:952-954.
95. Griffin JH. Blood coagulation. The thrombin paradox. Nature. 1995; 378:337-338.
96. De Agostini AI, Watkins SC, Slayter HS, Youssoufian H, Rosenberg RD. Localization of anticoagulantly active heparan sulfate proteoglycans in vascular endothelium: antithrombin binding on cultured endothelial cells and perfused rat aorta. J Cell Biol. 1990;111:1293-1304.
97. Hatton MWC, Moar SL, Richardson M. On the interaction of rabbit antithrombin III with the luminal surface of the normal and deendothelialized rabbit thoracic aorta in vitro. Blood. 1986;67:878-886.
98. Hatton MWC, Moar SL, Richardson M. Evidence that rabbit 1251-antithrombin III binds to proteoheparan sulfate at the subendothelium of the rabbit aorta in vitro. Blood Vessels. 1988;25:12-27.
99. Kolev K, Machovich R. Molecular and cellular modulation of fibrinolysis. Thromb Haemost. 2003;89:610-621.
100. Rasmussen HS, Rasmussen CS, Macko J, Yonehiro G. Angiogenic gene therapy strategies for the treatment of cardiovascular disease. Curr Opin Mol Ther. 2002;4:476-481.
101. Linhardt RT, Hileman RE. Dermatan sulfate as a potential therapeutic agent. Gen Pharmacol. 1995;26:443-451.
102. Baglin TP, Carrell RW, Church FC, Esmon CT, Huntington JA. Crystal structures of native and thrombin-complexed heparin cofactor II reveal a multistep allosteric mechanism. Proc Natl Acad Sci U S A. 2002;99: 11079-11084.
103. Nelson RM, Venot A, Bevilacqua MP, Linhardt RJ, Stamenkovic I. Carbohydrate-protein interactions in vascular biology. Annu Rev Cell Dev Biol. 1995;11:601-631.
104. Perretti M, Getting SJ. Migration of specific leukocyte subsets in response to cytokine or chemokine application in vivo. Methods Mol Biol. 2003;225:139-146.
105. Lander AD, Nie Q, Wan FYM. Do morphogen gradients arise by diffusion? Dev Cell. 2002;2:785-796.
106. Linhardt RJ, Toida T. Role of glycosaminoglycans in cellular communication. Acc Chem Res. 2004;37:431-438.
107. Swain SD, Rohn TT, Quinn MT. Neutrophil priming in host defense: role of oxidants as priming agents. Antioxid Redox Signal. 2002;4: 69-83.